Skip to content

A phase II randomized controlled trial comparing perioperative mFOLFOXIRI with perioperative chemoradiotherapy for locally advanced rectal cancer.

A phase II randomized controlled trial comparing perioperative mFOLFOXIRI with perioperative chemoradiotherapy for locally advanced rectal cancer. - A phase II randomized controlled trial comparing perioperative mFOLFOXIRI with perioperative chemoradiotherapy for locally advanced rectal cancer.

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000018624
Enrollment
34
Registered
2015-08-10
Start date
2015-08-20
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal cancer

Interventions

preoperative FOLFOXIRI+surgery preoperative chemoradiotherapy+surgery

Sponsors

Osaka Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Pathologically proven adenocarcinoma. 2. Primary tumor located at Rectosigmoid, Upper rectum, Lower rectum, and Anal canal.The lower border of the tumor located between the peritoneal reflection and the anal verge. 3. cT3and cT4a tumor on contrast-enhanced CT or MRI 4. Lateral lymph nodes without 7mm and more in short axis diameter on contrast-enhanced CT or MRI data of 5mm-thickness slices (cN0-cN2) . 5. No distant metastasis on contrast-enhanced CT or MRI (cM0) 6. Aged 20 to 74 years old 7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 8. Adequate organ function as evidenced by the following laboratory studies within 14 days prior to enrollment 1) Neutrophil count >= 1,500 /mm3 2) Platelet count >= 100,000 /mm3 3) Hemoglobin >= 9.0 g/dL 4) T.Bil =< 2.0 mg/dL 5) AST =< 100 IU/L, ALT =< 100 IU/L 6) Cr =< 1.5 mg/dL 9. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Currently treated with systemic steroids or immunosuppressive agent 2. Synchronous or metachronous (within 5 years) malignancies other than carcinoma in situ or mucosal carcinoma 3. Infectious disease to be treated 4. Positive for HBs antigen 5. Uncontrollable hypertension, Uncontrollable diabetes mellitus, Uncontrollable arrhythmia, and severe clinical problem 6. Grade 1 or more peripheral neuropathy 7. Women during pregnancy, possible pregnancy or breast-feeding 8. Severe mental disease 9. Attending physician determines that the case was inappropriate as the subject of this study

Design outcomes

Primary

MeasureTime frame
RFS:3 years relapse free survival

Secondary

MeasureTime frame
Response rate, Proportion of patients with R0 resection, Pathological response, 3 years progression free survival, 3 years overall survival, Incidence of adverse events, Proportion of operative complication, Proportion of anus-preservation without stoma, Evaluation of anal function, Evaluation of bladder function

Countries

Japan

Contacts

Public ContactKeitarou Tanaka

Osaka Medical College Hospital Department of general and gastroenterological surgery

sur036@poh.osaka-med.ac.jp072-683-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026